TRIDENT LIFELINE
|
The Current P/E Ratio of TRIDENT LIFELINE is 35.69.
Share Price | ₹300.0 | Oct 16,2025 |
Market Cap | ₹348.0 Cr | |
Earnings-TTM | ₹9.8 Cr | TTM-Consolidated Results |
Price/Earnings | 35.69x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of TRIDENT LIFELINE
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹348.0 Cr] as on Oct 16,2025
(/) Earnings [ ₹9.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 35.69x ]
Thus, for TRIDENT LIFELINE , the investors are currently willing to pay 35.69 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of TRIDENT LIFELINE !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of TRIDENT LIFELINE over the last five years.
Historical PE (Price/Earnings) ratio chart of TRIDENT LIFELINE
PE Ratio Performance Analysis for TRIDENT LIFELINE
- TRIDENT LIFELINE 's p/e ratio for fiscal years ending Mar2024 to Mar2022 averaged 20.04x.
- TRIDENT LIFELINE 's operated at median p/e ratio of 29.71x from fiscal years ending March 2018 to 2022.
- Looking back at the last 3 fiscal years, TRIDENT LIFELINE 's p/e ratio peaked in Mar2023 at 30.41x.
- TRIDENT LIFELINE 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does TRIDENT LIFELINE 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
TRIDENT LIFELINE | 9.75 | 35.69 | 348.0 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 38.25 | 398,218.0 |
DIVIS LABORATORIES LTD | 2,306.00 | 75.96 | 175,158.0 |
CIPLA LTD | 5,406.81 | 23.44 | 126,710.0 |
TORRENT PHARMACEUTICALS LTD | 2,002.00 | 59.73 | 119,586.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 18.07 | 103,496.0 |
MANKIND PHARMA LTD | 1,905.51 | 53.17 | 101,320.0 |
ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.35 | 99,013.4 |
LUPIN LTD | 3,722.18 | 23.94 | 89,093.5 |
AUROBINDO PHARMA LTD | 3,417.93 | 18.79 | 64,222.1 |
ABBOTT INDIA LTD | 1,452.29 | 43.65 | 63,398.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs TRIDENT LIFELINE 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.07x |
Max industry PE | 75.96x |
Median industry PE | 35.69x |
Average industry PE | 37.46x |
You may also like the below Video Courses